Bimekizumab use for 4 years among patients with plaque psoriasis is associated with sustained efficacy outcomes and no new safety signals.

Discover a study in which researchers examined three international cohorts of patients with moderate-to-severe psoriasis ...

For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers in blood, characterized by high-sensitivity C-reactive protein, despite ...

The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and ...

Learn to distinguish between nail psoriasis and nail fungus through key visual differences, associated symptoms, and treatment approaches for faster relief ...

The medical establishment is increasingly accepting of stress-reduction therapies that may be beneficial components of your psoriasis treatment ... doctor or pharmacist before you drink.

Pronounced “soh-TIK-too,” SOTYKTU is a once-daily pill for adults with moderate to severe plaque psoriasis that works inside ...

Forward-looking statements include statements regarding the potential of icotrokinra to shift the psoriasis treatment paradigm ... future events or otherwise, after the date of this press release.

Dermatologists are practicing in an “era of good efficacy” of nonsteroidal topical therapies for psoriasis ... it takes about 4 months [off treatment] before they experience mild severity ...

Switching from ustekinumab to biosimilar SB17 maintains long-term efficacy and safety in psoriasis patients, supporting cost-effective treatment ... ustekinumab after switching among patients ...

product development and clinical trials are needed before the method is ready for use. According to Andrea Heinz, though, it has great potential that extends beyond psoriasis treatment ...